Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
Go back to Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)| (NASDAQ: CVKD) | Delayed: 3.70 -0.33 (8.19%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.03 | 52 Week High | $ | |||
| Open | $4.05 | 52 Week Low | $ | |||
| Day High | $4.24 | P/E | N/A | |||
| Day Low | $3.70 | EPS | $ | |||
| Volume | 111,106 | |||||
